Abstract:The growing number of chemicals in the current consumer and industrial markets presents a major challenge for regulatory programs faced with the need to assess the potential risks they pose to human and ecological health. The increasing demand for hazard and risk assessment of chemicals currently exceeds the capacity to produce the toxicity data necessary for regulatory decision making, and the applied data is commonly generated using traditional approaches with animal models that have limited context in terms of human relevance. This scenario provides the opportunity to implement novel, more efficient strategies for risk assessment purposes. This study aims to increase confidence in the implementation of new approach methods in a risk assessment context by using a parallel analysis to identify data gaps in current experimental designs, reveal the limitations of common approaches deriving transcriptomic points of departure, and demonstrate the strengths in using high-throughput transcriptomics (HTTr) to derive practical endpoints. A uniform workflow was applied across six curated gene expression datasets from concentration-response studies containing 117 diverse chemicals, three cell types, and a range of exposure durations, to determine tPODs based on gene expression profiles. After benchmark concentration modeling, a range of approaches was used to determine consistent and reliable tPODs. High-throughput toxicokinetics were employed to translate in vitro tPODs (µM) to human-relevant administered equivalent doses (AEDs, mg/kg-bw/day). The tPODs from most chemicals had AEDs that were lower (i.e., more conservative) than apical PODs in the US EPA CompTox chemical dashboard, suggesting in vitro tPODs would be protective of potential effects on human health. An assessment of multiple data points for single chemicals revealed that longer exposure duration and varied cell culture systems (e.g., 3D vs. 2D) lead to a decreased tPOD value that indicated increased chemical potency. Seven chemicals were flagged as outliers when comparing the ratio of tPOD to traditional POD, thus indicating they require further assessment to better understand their hazard potential. Our findings build confidence in the use of tPODs but also reveal data gaps that must be addressed prior to their adoption to support risk assessment applications.

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing

Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing

Quantitative High-Throughput Screening for Chemical Toxicity in a Population-Based in Vitro Model.

Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics

Population-Based in Vitro Hazard and Concentration–Response Assessment of Chemicals: the 1000 Genomes High-Throughput Screening Study

From vision toward best practices: Evaluating in vitro transcriptomic points of departure for application in risk assessment using a uniform workflow

A Population-Based Human in Vitro Approach to Quantify Inter-Individual Variability in Responses to Chemical Mixtures

Reducing uncertainty in dose-response assessments by incorporating Bayesian benchmark dose modeling and in vitro data on population variability

In Vitro Screening of Environmental Chemicals for Targeted Testing Prioritization: The ToxCast Project

In vitro to in vivo extrapolation for high throughput prioritization and decision making

Exploring the effects of experimental parameters and data modeling approaches on in vitro transcriptomic point-of-departure estimates

Discovery Phase Agrochemical Predictive Safety Assessment Using High Content In Vitro Data to Estimate an In Vivo Toxicity Point of Departure

Predictive value of the ToxCast/Tox21 high throughput toxicity screening data for approximating in vivo ecotoxicity endpoints and ecotoxicological risk in eco- surveillance applications

Integrating in vitro metabolomics with a 96-well high-throughput screening platform

Physiologically Based Pharmacokinetic (pbpk) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse

Evaluating the impact of anatomical and physiological variability on human equivalent doses using PBPK models

Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing

Dosing Methods to Enable Cell-Based In Vitro Testing of Complex Substances: A Case Study with a PAH Mixture

Using ToxCast™ Data to Reconstruct Dynamic Cell State Trajectories and Estimate Toxicological Points of Departure.

Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling

Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment